Perioperative blood transfusion and postoperative mortality

Article Abstract:

Blood transfusions for moderate anemia may not reduce postoperative mortality rates among elderly surgical patients. Researchers compared mortality rates and transfusion patterns for 8,787 patients aged 60 and older who had surgical repair of fractured hips. Most patients with severe anemia were transfused, as were about half with moderate anemia. Transfusions around the time of surgery for hemoglobin levels of 8 milligrams per deciliter or higher did not affect the mortality rates one to three months after surgery. The benefits of blood transfusion in moderate anemia may need reassessment.

Care and treatment, Anemia, Blood transfusion, Blood cell count

---

Parenteral ketorolac: the risk for acute renal failure

Article Abstract:

Short-term use of ketorolac does not seem to increase the risk for kidney failure compared to opiate medications. The incidence and risk for kidney failure were compared among 9,850 patients treated with ketorolac and 10,145 patients treated with opiate medication. Only 1.1% of either group had kidney failure following treatment. Overall risk for kidney failure and risk during the first five days of treatment was equal for both treatments. However, risk for kidney failure was significantly higher for patients treated with ketorolac longer than five days.

Complications and side effects, Risk factors, Parenteral nutrition, Parenteral therapy, Acute renal failure, Acute kidney failure, Ketorolac

---

The effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis of individual patient-level data

Article Abstract:

Antilymphocyte induction therapy may be beneficial in certain patients to prevent rejection of a kidney transplant. This therapy blocks the immune response that might lead to graft rejection. Researchers evaluated the medical literature on the use of this therapy in kidney transplant recipients. In 628 patients in which this therapy was tried, graft failure during the first two years was less likely in those who received the therapy, but this benefit did not last longer than five years.

Prevention, Graft rejection, Kidneys, Kidney transplantation, Immunotherapy

Similar abstracts:

• Abstracts: Post-operative care of transplant patients. Heart to heart. Life in the balance
• Abstracts: In utero hematopoietic stem cell transplantation: a status report. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow
• Abstracts: Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS. Protease inhibitors
• Abstracts: This I believe ... about the care of human beings. When negligence becomes homicide. 100 years: a nurses' dreaming
• Abstracts: Corporate liability: security and violence. Labor law update

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.